Emergent BioSolutions gets $52.7 million ACAM2000 contract modification from ASPR

Emergent BioSolutions announced on June 29, 2026 that it received a contract modification valued at approximately $52.7 million from the Administration for Strategic Preparedness and Response, part of the U.S. Department of Health and Human Services, for its smallpox and mpox vaccine ACAM2000. The modification covers supply of ACAM2000 vaccine, ancillaries, and diluent replacement lots for smallpox preparedness and response needs.¹

According to the company's 8-K, Emergent's wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received the modification, designated Modification No. 15, on June 26, 2026, exercising Option Year 7 under the existing 10-year ACAM2000 contract with ASPR.¹ Modification No. 15 is valued at $52.7 million and requires Emergent to deliver doses of ACAM2000, ancillaries, and diluent replacement lots to the U.S. government in June 2026, with any remaining balance of diluent due by December 2026.¹

The press release states more broadly that deliveries are expected to begin this month¹, referring to June 2026, consistent with the 8-K's specification that initial deliveries are due within that month.

This contract modification falls under Emergent's existing 10-year contract, numbered 75A50119C00071, with ASPR.¹ The award follows recent announcements that Saudi Arabia's Food and Drug Authority approved ACAM2000 for immunization against smallpox and mpox in high-risk individuals, and that Singapore's Health Sciences Authority approved an expanded indication for the vaccine covering mpox prevention in high-risk adults.¹

A copy of Modification 15 is expected to be filed as an exhibit to the company's next Quarterly Report on Form 10-Q, and the underlying ACAM2000 contract was previously filed as Exhibit 10.48 to Emergent's 2019 Annual Report on Form 10-K.¹